Therefore, We should fully evaluate the risk of recurrence of breast cancer patients, such as hormone receptor status, HER2 expression, lymph node metastasis, etc., and then choose the appropriate treatment plan to bring the greatest benefit to patients. This evidence concerns the gene ERBB2 and breast cancer.